RTSN Retension Pharmaceuticals, Inc.
Fundamentals / CIK 0002002988 / USDRetension Pharmaceuticals, Inc. reported $14.15M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open RTSN in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$9.19M Total debt: --
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Research & Development | $5.02M | -- | -- | $1.37M | -- | -- |
| Total Operating Expenses | $6.01M | -- | -- | $1.66M | -- | -- |
| Operating Income | -$6.01M | -- | -- | -$1.66M | -- | -- |
| Interest Income | $89K | -- | -- | $189K | -- | -- |
| Net Income | -$5.92M | -$4.14M | -$3.38M | -$1.48M | -$1.23M | -$656K |
| Basic EPS | -$7.33 | -- | -- | -$1.83 | -- | -- |
| Diluted EPS | -$7.33 | -- | -- | -$1.83 | -- | -- |
| Basic Shares Outstanding | 807.9K | -- | -- | 805.2K | -- | -- |
| Diluted Shares Outstanding | 807.9K | -- | -- | 805.2K | -- | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2025-12-31 |
|---|---|---|
| Cash & Cash Equivalents | $9.19M | $18.90M |
| Cash & Short-Term Investments | $9.19M | $18.90M |
| Total Current Assets | $14.15M | $21.45M |
| Total Non-Current Assets | $0 | $0 |
| Total Assets | $14.15M | $21.45M |
| Accounts Payable | $3.89M | $776K |
| Total Current Liabilities | $6.66M | $912K |
| Total Non-Current Liabilities | $0 | $0 |
| Total Liabilities | $6.66M | $912K |
| Common Stock | $81 | $81 |
| Retained Earnings | -$21.76M | -$8.32M |
| Total Stockholders' Equity | -$20.66M | -$7.78M |
| Total Equity | -$20.66M | -$7.78M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$5.92M | -$4.14M | -$3.38M | -$1.48M | -$1.23M | -$656K |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 2.12x | -- | -- | -- | -- | -- |
| Quick Ratio | 1.38x | -- | -- | -- | -- | -- |